HENDERSONVILLE, TN / ACCESSWIRE / April 7, 2020 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 19 years, reminds investors that a purchaser of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between December 3, 2018 and February 10, 2020. LogicBio is a genome editing company that focuses on developing medicines to treat rare diseases in patients. LogicBio's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia ("MMA").
LogicBio Therapeutics, Inc. (LOGC) Accused of Misleading Shareholders
According to the complaint, on April 1, 2019, LogicBio released its full year 2018 financial results, touting the Company's progress with LB-001 and stating "the Company continues to advance its lead product candidate to an expected Investigational New Drug (IND) by the end of 2019" and into a Phase 1/2 clinical trial in MMA patients in 2020. Throughout the relevant period, LogicBio continued to affirm LB-001's progress and timeline, and on January 10, 2020, the Company announced the submission of its IND with the U.S. Food and Drug Administration (FDA). Despite LogicBio's confidence in LB-001's IND, on February 10, 2020, LogicBio revealed that "the [FDA] has placed a clinical hold on the [IND] submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions." On this news, LogicBio's share price fell almost 32%, to close at $7.11 per share. The stock continues to decline.
LogicBio Shareholders Urged to Contact the Firm
If you purchased LogicBio securities, have information, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Timothy L. Miles, Esquire, at 615-587-7384, Toll-Free at 855-846-6529, or by email to [email protected]. If you inquire by email please include your mailing address, telephone number, and the number shares owned.
About Timothy L. Miles
Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles was recentely selected by Martindale-Hubbell® and ALM as a 2020 Top Ranked Lawyer and a 2020 Top Rated Litigator. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019). Awards: Top Rated Litigator by Martindale-Hubbell® and ALM (2019); 2019 Elite Lawyer of The South by Martindale-Hubbell® and ALM (2019); Member of the Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association (2017-2019); AV® Preeminent™ Rating by Martindale-Hubble® (2014-2020); PRR AV Preeminent Rating on Lawyers.com (2017 & 2019); The Top-Rated Lawyer in Litigation™ for Ethical Standards and Legal Ability (Martindale-Hubble® 2015); Lifetime Achievement Award by Premier Lawyers of America (2019); Superb Rated Attorney (Avvo); Avvo Top Rated Lawyer for 2017 & 2018 (Avvo). Mr. Miles has authored numerous publications advocating for shareholdings including most recently: Free Portfolio Monitoring Services Offered by Plaintiff Securities Firms Provides Significant Benefits To Investors (Timothy L. Miles, Dec. 3, 2019).
Contact:
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
124 Shiloh Ridge
Hendersonville, TN 37075
Telephone: (855-846-6529)
Email: [email protected] Website: www.timmileslaw.com
SOURCE: The Law Offices of Timothy L. Miles